Super circulating tumor infiltrating lymphocytes(ScTIL)

BIOLOGICAL2 trials

Sponsors

Peking University Cancer Hospital & Institute, Shanghai East Hospital

Conditions

Malignant Solid TumorMelanoma

Phase 1

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

Peking University Cancer Hospital & InstituteMelanoma

Start: 2020-05-31End: 2021-12-31Target: 32Updated: 2020-04-24

A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors

Shanghai East HospitalMalignant Solid Tumor

Start: 2020-10-15End: 2024-12-31Target: 58Updated: 2023-04-12